Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Donna S. Neuberg, D.Sc.

Co-Author

This page shows the publications co-authored by Donna Neuberg and Jon Aster.
Connection Strength

0.370
  1. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 07 13; 547(7662):217-221.
    View in: PubMed
    Score: 0.046
  2. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. 2016 Nov 14; 30(5):750-763.
    View in: PubMed
    Score: 0.044
  3. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
    View in: PubMed
    Score: 0.043
  4. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
    View in: PubMed
    Score: 0.043
  5. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2007 May 01; 25(13):1741-6.
    View in: PubMed
    Score: 0.023
  6. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A. 2006 Nov 28; 103(48):18261-6.
    View in: PubMed
    Score: 0.022
  7. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 1):3265-71.
    View in: PubMed
    Score: 0.022
  8. A zebrafish bmyb mutation causes genome instability and increased cancer susceptibility. Proc Natl Acad Sci U S A. 2005 Sep 13; 102(37):13194-9.
    View in: PubMed
    Score: 0.020
  9. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005 Aug 15; 106(4):1392-9.
    View in: PubMed
    Score: 0.020
  10. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005 Mar 01; 105(5):1851-61.
    View in: PubMed
    Score: 0.019
  11. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003 Dec 01; 102(12):3871-9.
    View in: PubMed
    Score: 0.018
  12. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002 Jan; 8(1):68-74.
    View in: PubMed
    Score: 0.016
  13. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998 Jan; 16(1):13-8.
    View in: PubMed
    Score: 0.012
  14. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood. 1997 Nov 15; 90(10):4212-21.
    View in: PubMed
    Score: 0.012
  15. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1994 Dec; 12(12):2535-42.
    View in: PubMed
    Score: 0.010
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.